Back to search

Peptide record

TPDB92278

SHIVA 10 PEPTIDE 71 + KWKL SHIVA DERIV P69 + KWKL Antibacterial Anticancer Antifungal Hemolysis Toxicity standard

22 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92278

Peptide_Name

SHIVA 10 PEPTIDE 71 + KWKL SHIVA DERIV P69 + KWKL

Activity

Antibacterial Anticancer Antifungal Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 22-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, ACP740 _ACP240, AntiCP 2.0, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FAKKLAKKLKKLAKKLAKKWKL-NH2

FASTA

>TPDB92278|Antibacterial;Anticancer;Antifungal;Hemolysis;Toxicity|length=22
FAKKLAKKLKKLAKKLAKKWKL-NH2

Formula C128H228N34O23

Absent Amino Acids RNDCEQGHIMPSTYV

Common Amino Acids K

Mass 2611.43

PI 11.51

Basic Residues 11

Acidic Residues 0

Hydrophobic Residues 11

Net Charge +11

Boman Index 4.43

Hydrophobicity -0.673

Aliphatic Index 106.82

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 210.61

Polar Residues 0

number

Amino Acid Distribution

A: 4 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 11 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0

Length

Formula

C128H228N34O23

Mass

2611.43

11.51

Net Charge

+11

Boman Index

4.43

Hydrophobicity

-0.673

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

FLAK peptides

Evidence 1 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =44 µg/ml

Detail Source Activity Anticancer

Activity Measurement 44 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =93 µg/ml

Detail Source Activity Anticancer

Activity Measurement 93 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 3 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =11 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 4 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =82 µg/ml

Detail Source Activity Anticancer

Activity Measurement 82 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 5 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =94 µg/ml

Detail Source Activity Anticancer

Activity Measurement 94 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 6 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =290 µg/ml

Detail Source Activity Anticancer

Activity Measurement 290 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 7 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =63 µg/ml

Detail Source Activity Anticancer

Activity Measurement 63 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 8 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =82 µg/ml

Detail Source Activity Anticancer

Activity Measurement 82 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 9 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =28 µg/ml

Detail Source Activity Anticancer

Activity Measurement 28 µg/mL

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2